Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DG0NA1
|
|||
| Drug Name |
MEDI1191
|
|||
| Drug Type |
mRNA therapy
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
AstraZeneca; Moderna Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukine 12 (IL-12) | Target Info | Replacement | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03946800) A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.